TRL Trilogy International Partners Inc

0.24

0.00 (0.00%)

31 May 2024 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type
Trilogy International Partners Inc	TSX:TRL	Toronto	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	0.24	0.20	0.275				0	01:00:00

Trimel Pharmaceuticals - Seeking positive EBITDA with Estrace

06/08/2014 5:27am

InvestorsHub NewsWire

Trimel (TSX:TRL) has acquired Canadian rights to Estrace (oral 17-beta estradiol) for C$44.5m from Shire. This profitable asset, with US$9-10m in annual sales, complements Trimel's existing hormone replacement pipeline. The transaction fits with the goal to become EBITDA positive within 12-18 months, although future Natesto-related revenue (upon completion of a partnership transaction) will be the key driver towards this objective.

Trimel is a Canadian specialty pharmaceutical company. Natesto and Tefina deliver testosterone through a bio-adhesive nasal gel drug delivery technology platform, for male hypogonadism and female orgasmic disorder (FOD), respectively. Estrace is being marketed for HRT in Canada.

To view the full report, click on the following link: http://www.edisoninvestmentresearch.com/research/report/trimel-pharmaceuticals-

To view all of Edison's recently pubished research, click here.